These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 39083015)

  • 1. Immune and Gene-expression Profiling in Estrogen Receptor Low and Negative Early Breast Cancer.
    Massa D; Vernieri C; Nicolè L; Criscitiello C; Boissière-Michot F; Guiu S; Bobrie A; Griguolo G; Miglietta F; Vingiani A; Lobefaro R; Taurelli Salimbeni B; Pinato C; Schiavi F; Brich S; Pescia C; Fusco N; Pruneri G; Fassan M; Curigliano G; Guarneri V; Jacot W; Dieci MV
    J Natl Cancer Inst; 2024 Jul; ():. PubMed ID: 39083015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
    Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
    Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
    Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
    Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration.
    Liu S; Foulkes WD; Leung S; Gao D; Lau S; Kos Z; Nielsen TO
    Breast Cancer Res; 2014 Sep; 16(5):432. PubMed ID: 25193543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune characterization of breast cancer metastases: prognostic implications.
    Dieci MV; Tsvetkova V; Orvieto E; Piacentini F; Ficarra G; Griguolo G; Miglietta F; Giarratano T; Omarini C; Bonaguro S; Cappellesso R; Aliberti C; Vernaci G; Giorgi CA; Faggioni G; Tasca G; Conte P; Guarneri V
    Breast Cancer Res; 2018 Jun; 20(1):62. PubMed ID: 29929548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate,
    Sobral-Leite M; Van de Vijver K; Michaut M; van der Linden R; Hooijer GKJ; Horlings HM; Severson TM; Mulligan AM; Weerasooriya N; Sanders J; Glas AM; Wehkamp D; Mittempergher L; Kersten K; Cimino-Mathews A; Peters D; Hooijberg E; Broeks A; van de Vijver MJ; Bernards R; Andrulis IL; Kok M; de Visser KE; Schmidt MK
    Oncoimmunology; 2018; 7(12):e1509820. PubMed ID: 30524905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune landscape of breast tumors with low and intermediate estrogen receptor expression.
    Voorwerk L; Sanders J; Keusters MS; Balduzzi S; Cornelissen S; Duijst M; Lips EH; Sonke GS; Linn SC; Horlings HM; Kok M
    NPJ Breast Cancer; 2023 May; 9(1):39. PubMed ID: 37179445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Assessment of Immune Phenotype and Its Effects on Survival Outcomes in HER2-Low versus HER2-Zero Breast Cancer.
    Ko HC; Seager RJ; Pabla S; Senosain MF; Van Roey E; Gao S; Strickland KC; Previs RA; Green MF; Cooper M; Nesline MK; Hastings SB; Amoah KA; Zhang S; Conroy JM; Jensen TJ; Eisenberg M; Caveney B; Severson EA; Ramkissoon S; Gandhi S
    Breast Cancer (Dove Med Press); 2024; 16():483-495. PubMed ID: 39192887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Standardized Evaluation Method for FOXP3+ Tregs and CD8+ T-cells in Breast Carcinoma: Association With Breast Carcinoma Subtypes, Stage and Prognosis.
    Papaioannou E; Sakellakis M; Melachrinou M; Tzoracoleftherakis E; Kalofonos H; Kourea E
    Anticancer Res; 2019 Mar; 39(3):1217-1232. PubMed ID: 30842152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
    de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
    Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up.
    Lundgren C; Bendahl PO; Ekholm M; Fernö M; Forsare C; Krüger U; Nordenskjöld B; Stål O; Rydén L
    Breast Cancer Res; 2020 Dec; 22(1):140. PubMed ID: 33357231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High tumor-infiltrating FoxP3
    Qian F; Qingping Y; Linquan W; Xiaojin H; Rongshou W; Shanshan R; Wenjun L; Yong H; Enliang L
    Eur J Surg Oncol; 2017 Jul; 43(7):1258-1264. PubMed ID: 28214052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
    Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
    Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical, Epidemiologic, and Pathologic Significance of ERBB2-Low Expression in Breast Cancer.
    Khoury T; Mendicino L; Payne Ondracek R; Yao S; Davis W; Omilian AR; Kwan ML; Roh JM; D'Addario L; Valice E; Fernandez D; Ergas IJ; Chua AV; Ambrosone CB; Kushi LH
    JAMA Netw Open; 2024 Mar; 7(3):e243345. PubMed ID: 38517439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers.
    Jumppanen M; Gruvberger-Saal S; Kauraniemi P; Tanner M; Bendahl PO; Lundin M; Krogh M; Kataja P; Borg A; Fernö M; Isola J
    Breast Cancer Res; 2007; 9(1):R16. PubMed ID: 17263897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune microenvironment dynamics in breast cancer during pregnancy: impact of gestational age on tumor-infiltrating lymphocytes and prognosis.
    Sajjadi E; Venetis K; Ivanova M; Noale M; Blundo C; Di Loreto E; Scarfone G; Ferrero S; Maggi S; Veronesi P; Galimberti VE; Viale G; Peccatori FA; Fusco N; Guerini-Rocco E
    Front Oncol; 2023; 13():1116569. PubMed ID: 37671051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effector memory cytotoxic CD3
    Sun X; Zhai J; Sun B; Parra ER; Jiang M; Ma W; Wang J; Kang AM; Kannan K; Pandurengan R; Zhang S; Solis LM; Haymaker CL; Raso MG; Mendoza Perez J; Sahin AA; Wistuba II; Yam C; Litton JK; Yang F
    Mod Pathol; 2022 May; 35(5):601-608. PubMed ID: 34839351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
    Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
    Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies.
    Zhao J; Meisel J; Guo Y; Nahta R; Hsieh KL; Peng L; Wei Z; O'Regan R; Li X
    Breast Cancer Res Treat; 2020 Oct; 183(3):599-606. PubMed ID: 32715443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes.
    Sobral-Leite M; Salomon I; Opdam M; Kruger DT; Beelen KJ; van der Noort V; van Vlierberghe RLP; Blok EJ; Giardiello D; Sanders J; Van de Vijver K; Horlings HM; Kuppen PJK; Linn SC; Schmidt MK; Kok M
    Breast Cancer Res; 2019 Aug; 21(1):90. PubMed ID: 31391067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.